Hinge Health (NYSE:HNGE) President Sells $2,287,230.00 in Stock

Hinge Health Inc. (NYSE:HNGE) President James Pursley sold 33,000 shares of Hinge Health stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $69.31, for a total transaction of $2,287,230.00. Following the completion of the transaction, the president directly owned 740,897 shares in the company, valued at approximately $51,351,571.07. This represents a 4.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Pursley also recently made the following trade(s):

• On Tuesday, May 26th, James Pursley sold 16,000 shares of Hinge Health stock. The stock was sold at an average price of $53.79, for a total transaction of $860,640.00.

Hinge Health Trading Up 6.1%

NYSE:HNGE opened at $74.86 on Friday. The firm has a market capitalization of $5.79 billion and a PE ratio of -6.07. Hinge Health Inc. has a 1 year low of $30.08 and a 1 year high of $75.17. The firm’s fifty day simple moving average is $56.17 and its 200 day simple moving average is $47.33.

Hinge Health (NYSE:HNGE) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.33. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The company had revenue of $182.31 million during the quarter. During the same quarter last year, the company earned $1.30 earnings per share. The firm’s revenue was up 47.2% on a year-over-year basis. As a group, analysts anticipate that Hinge Health Inc. will post 1.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Raymond James Financial upped their target price on shares of Hinge Health from $70.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, June 15th. Piper Sandler reaffirmed an “overweight” rating on shares of Hinge Health in a research report on Wednesday, June 10th. Zacks Research raised Hinge Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Wells Fargo & Company boosted their price target on Hinge Health from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Needham & Company LLC upped their price target on Hinge Health from $63.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $75.80.

Trending Headlines about Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Hinge Health raised its Q2 2026 revenue guidance to $200 million-$202 million, above the Street’s $195 million estimate, and lifted full-year 2026 revenue guidance to $818 million-$824 million versus consensus of $801.6 million, signaling better-than-expected growth momentum.
• Positive Sentiment: Recent operating results remain strong, with the company’s last reported quarter showing 47.2% revenue growth and earnings that beat analyst expectations, helping support bullish sentiment around the stock.
• Neutral Sentiment: Wall Street remains broadly constructive on Hinge Health, with recent analyst price targets ranging from the high-$70s to $90 and a consensus rating of Moderate Buy, suggesting investors still see upside potential.
• Negative Sentiment: Insight Holdings Group, a major shareholder, sold multiple large blocks of HNGE shares in recent days, including transactions on June 22, June 23, and June 24. Although the sales were made under a pre-arranged Rule 10b5-1 plan, the volume of selling may pressure sentiment. SEC filing
• Negative Sentiment: President James Pursley also sold 33,000 shares, adding to the cluster of insider sales and raising questions about valuation after the stock’s recent run-up. SEC filing

Hedge Funds Weigh In On Hinge Health

A number of hedge funds have recently made changes to their positions in the business. Janney Montgomery Scott LLC raised its stake in shares of Hinge Health by 3.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 9,400 shares of the company’s stock valued at $362,000 after buying an additional 300 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Hinge Health by 160.0% during the 4th quarter. Wells Fargo & Company MN now owns 546 shares of the company’s stock valued at $25,000 after acquiring an additional 336 shares in the last quarter. Lazard Asset Management LLC increased its stake in Hinge Health by 0.6% in the first quarter. Lazard Asset Management LLC now owns 63,705 shares of the company’s stock valued at $2,456,000 after acquiring an additional 386 shares during the period. First Horizon Corp increased its stake in Hinge Health by 163.9% in the fourth quarter. First Horizon Corp now owns 855 shares of the company’s stock valued at $40,000 after acquiring an additional 531 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Hinge Health in the fourth quarter worth about $26,000.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.